New Delhi, Nov 10 (PTI) Novo Nordisk India and Emcure Pharma on Monday announced a partnership to launch the weight-loss medicine Poviztra, semaglutide injection 2.4 mg, as a second brand of Wegovy in India.

Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025.

It is indicated for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity, as an adjunct to a reduced-calorie diet and increased physical activity, the two companies said in a joint statement.

The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India, it added.

“Obesity is a serious chronic disea

See Full Page